More Data Support Olaparib-Abiraterone in BRCA-Mutant Prostate Cancer
Meeting Coverage > > GuCS Video Pearls-- BRCAAway trial verifies function of mix in first-line setting
by Greg Laub, Director, Video, MedPage Today February 15, 2024
Integrating olaparib (Lynparza) with abiraterone acetate (Zytiga) as first-line treatment for biomarker-selected clients with metastatic castration-resistant prostate cancer considerably enhanced progression-free survival (PFS) versus either representative alone, according to findings from a little stage II trial provided at this year's Genitourinary Cancers Symposium.
In this special MedPage Today video, Daniel Geynisman, MD, of Fox Chase Cancer Center in Philadelphia, w...